In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) ...

A recent publication in the International Journal of Cardiology, "Pulmonary artery denervation in pulmonary hypertension: A ...

People who live with chronic diseases such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), connective tissue diseases (CTD), chronic kidney disease (CKD), liver ...

Corvista Health’s point-of-care device, used to predict pulmonary hypertension (PH), also appears to work well at identifying ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Not everybody with blockages needs surgical intervention. Guidelines recommend against surgery in people with no symptoms and less than 70% stenosis. Only when the blockage is greater than 70% is ...

Not everybody with blockages needs surgical intervention. Guidelines recommend against surgery in people with no symptoms and ...

I have HIV and pulmonary hypertension. I was part of a research study, and a scan found blockages of about 50% in my carotid arteries. I’ve never had any symptoms or a stroke. Do I need to have ...

Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and pulmonary hypertension were found.